Sun Pharmaceutical Industries has received CDSCO approval to manufacture and market a generic once-daily oral semaglutide in India for type-2 diabetes, covering 3 mg, 7 mg and 14 mg strengths, according to a report by ETPharma. The approval adds a third generic oral entrant to a market where Torrent Pharma already holds nearly 90 percent of oral generic semaglutide share, and it arrives as the combined Indian GLP-1 market, injectables and orals together, has nearly tripled to Rs 2,700 crore from Rs 950 crore in 2025, per PharmaTrac estimates.
The nut graf for the peptide therapy and research peptide industry is straightforward: oral semaglutide is the formulation that decides whether GLP-1 demand stays inside branded prescription channels or spreads into the clinic, telehealth and compounding ecosystems that already handle peptide medicines. Every new generic oral entrant changes price benchmarks, supply-chain sourcing and the compliance questions that peptide therapy clinics and research peptide suppliers face when they discuss semaglutide with patients and buyers.
What happened: CDSCO clears Sun Pharma’s oral semaglutide
Sun Pharma’s formulation is a once-daily tablet approved for type-2 diabetes, and the company describes it as therapeutically equivalent to Novo Nordisk’s Rybelsus. That equivalence statement is attributed to Sun Pharma in the ETPharma report; it is a company characterization, not an independent bioequivalence finding published in a peer-reviewed journal.
The product is an r-DNA origin product to be manufactured at Sun Pharma’s Kamrup, Assam facility, with the active ingredient sourced from China’s Zhongmeihuadong Pharmaceutical in Hangzhou. No launch date and no pricing were disclosed. ETPharma said it reached out to Sun Pharma for comment and that a response was awaited at the time of publication.
The regulatory milestone is manufacturing and marketing approval, not a commercial launch. In practice, approval and launch are separate events: supply agreements, packaging, distribution and pricing decisions typically follow approval, and none of those details appear in the available reporting.
Key numbers behind the Indian semaglutide market
The competitive picture is already crowded. Torrent Pharma became the first drugmaker to launch generic oral semaglutide, under the brand names Semalix and Sembolic, after the Delhi High Court ruled that its formulation did not infringe Novo’s patent. Dr Reddy’s then launched its own oral brand, Obeda, at Rs 99, Rs 135 and Rs 225 per tablet for the 3 mg, 7 mg and 14 mg strengths respectively.
Sun Pharma is not a newcomer to semaglutide. It already markets two injectable brands, Noveltreat for weight management and Sematrinity for type-2 diabetes, which recorded Rs 19 crore and Rs 16 crore respectively until September this year.
| Item | Figure | Source / status |
|---|---|---|
| Indian GLP-1 market (injectables + orals), latest estimate | Rs 2,700 crore | PharmaTrac estimates, as reported |
| Indian GLP-1 market prior figure cited | Rs 950 crore in 2025 | PharmaTrac estimates, as reported |
| Torrent Pharma share of oral generic semaglutide market | ~90% | Reported, not independently verified |
| Dr Reddy’s Obeda price per tablet (3 / 7 / 14 mg) | Rs 99 / Rs 135 / Rs 225 | Company launch, as reported |
| Sun Pharma oral semaglutide strengths | 3 mg, 7 mg, 14 mg | CDSCO approval, as reported |
| Sun Pharma injectable semaglutide sales to September | Noveltreat Rs 19 crore; Sematrinity Rs 16 crore | Reported |
Why it matters for peptide therapy and research peptide supply chains
Semaglutide is a GLP-1 receptor agonist peptide, and the oral route is technically demanding. Oral peptide delivery depends on absorption-enhancer formulation technology, tight control of impurities and consistent tablet performance, which is why the oral formulation remained under a separate patent in India even after semaglutide lost patent protection in March this year. That split between base-compound expiry and formulation-level protection is the legal hinge on which the whole generic oral wave turns.
For peptide therapy clinics and telehealth operators, the practical consequence is price transparency. When a generic oral tablet is available at Rs 99 to Rs 225 per tablet, the reference price for a month of therapy becomes visible to patients, and clinics that source compounded or imported semaglutide must be able to explain why their offering differs in regulatory status, documentation and cost. This is a commercial and compliance conversation, not a claim about comparative efficacy.
For research peptide businesses, the more relevant signal is sourcing discipline. Sun Pharma’s disclosure that its API comes from a named Chinese manufacturer underscores how concentrated GLP-1 peptide API supply remains. Buyers evaluating peptide suppliers should apply the same logic described in industry quality guidance: confirm exact chemical identity, salt form, molecular weight, batch-specific analytical data and the analytical method used, and treat a certificate of analysis as a batch document rather than proof of clinical suitability. Platforms that track supplier documentation, such as peptidescm, exist precisely because that verification work is repetitive and error-prone.
It is worth restating the regulatory boundary. A generic oral semaglutide approved by CDSCO for type-2 diabetes in India is a prescription medicine in its own jurisdiction. It is not a research peptide, and research-use-only materials should never be presented as equivalent to an approved product. Conversely, approval of a branded generic in one country does not authorize importation, compounding or clinical use elsewhere; those questions depend on the rules of the destination market.
Research and market context: what the evidence does and does not show
Incretin-based drugs, which mimic gut hormones such as GLP-1 to improve glycaemic control, have steadily outgrown their original diabetes role, and the Indian market’s expansion followed the entry of newer molecules including Novo’s semaglutide and Eli Lilly’s tirzepatide, according to the PharmaTrac-based reporting. That attribution is directional rather than decomposed: the available figures do not isolate how much of the growth came from new molecules, from obesity prescribing, from pricing changes or from channel expansion.
Penetration in India remains relatively low. On the post-Q2 FY27 analyst call, Sun Pharma Executive Chairman Dilip Shanghvi said that even capturing a few percentage points of the total patient population would still leave a very large product. That is a management assertion about market size, not a measured forecast, and it should be read alongside affordability and prescribing-capacity constraints that the reporting does not quantify.
Oral formulations are also described as opening a new market opportunity amid intensifying competition and price erosion in the injectable segment. Industry observers note that this is an inference about competitive dynamics rather than a measured substitution effect; orals may expand the total market instead of displacing injectables, and the current data cannot distinguish between the two.
For readers tracking GLP-1 clinical literature, the distinction between formulation news and efficacy evidence matters. A regulatory approval of a generic oral product rests on a regulatory dossier; it does not add new randomized trial evidence about outcomes. Anyone citing this approval as new proof of clinical benefit would be misreading the evidence type.
What comes next: launch pricing, share shifts and documentation
Three unknowns will determine how much this approval changes the Indian market. First, Sun Pharma’s launch price: without it, any projection of share shift away from Torrent’s roughly 90 percent oral position is speculative. Second, supply continuity from the Kamrup facility and from the named API source, since GLP-1 peptide manufacturing capacity is a global constraint rather than a local one. Third, whether other generic filers secure their own approvals or court outcomes, which would further compress oral pricing.
For clinics, distributors and research suppliers watching the GLP-1 category, the useful discipline is documentary rather than promotional: track approval status by jurisdiction, keep batch-level analytical records, and separate prescription products from research materials in both inventory and communication. Supply-chain intelligence services such as PeptideDDP are used by operators who need first-hand visibility into sourcing and logistics changes before they appear in headline pricing.
This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
FAQ
Did Sun Pharma receive approval to sell oral semaglutide in India?
Yes. According to ETPharma, CDSCO granted Sun Pharmaceutical Industries approval to manufacture and market a generic once-daily oral semaglutide for type-2 diabetes in 3 mg, 7 mg and 14 mg strengths. No launch date or price has been disclosed.
Is Sun Pharma’s oral semaglutide the same as Rybelsus?
Sun Pharma describes its formulation as therapeutically equivalent to Novo Nordisk’s Rybelsus. That is a company statement reported by ETPharma; the available reporting does not include independently published bioequivalence data.
Why are generic oral semaglutide products launching if the patent expired?
Semaglutide lost patent protection in March this year, but the oral formulation remains covered by a separate patent in India. Torrent Pharma launched first after the Delhi High Court ruled its formulation did not infringe Novo’s patent.
Does this approval mean oral semaglutide is available without a prescription?
No. The approval covers a prescription medicine for type-2 diabetes in India. It does not authorize use in other countries, and it does not make research-use-only semaglutide products equivalent to an approved medicine.
How large is the Indian GLP-1 market?
According to PharmaTrac estimates cited in the reporting, the combined GLP-1 market for injectables and orals nearly tripled to Rs 2,700 crore from Rs 950 crore in 2025.
Comments